Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

IMTX•2026-07-17

Timing of abstracts and presentations

Abstracts are scheduled for release on Oct. 19, 2026; presentations run Oct. 23-24 during ESMO in Madrid.

ESMO 2026 presentations across PRAME franchise

Immatics flagged three ESMO Congress 2026 presentations as key updates across its PRAME franchise spanning cell therapies and a bispecific program.

New Phase 1b data for lead PRAME cell therapy anzu-cel in metastatic cutaneous and uveal melanoma will focus on predictors of durable response.

Phase 1 results for IMA203CD8 across PRAME-positive solid tumors will include durability follow-up at clinically relevant dose levels in gynecologic cancers.

Phase 1b data for PRAME bispecific IMA402 at the recommended Phase 2 dose range across multiple cancers will support expansion and combination plans.

Sources

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

Publicnow

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

Timing of abstracts and presentations

ESMO 2026 presentations across PRAME franchise

Related News

Realty Income announces monthly distribution of R$ 0.47 per unit, payable July 21

Laser Photonics says warrant exercise to raise USD 2.5 million gross proceeds

Intuitive Surgical falls as Obamacare uncertainties cloud forecast

Sources

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

US regional banks brush off war jitters with lending surge, fee boost

Greenland Mines CFO Jeff LeBlanc acquires 1,400,000 common shares for $245,280